Barclays Sticks to Their Buy Rating for Alector (ALEC)
Alector Analyst Ratings
Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), Revance Therapeutics (RVNC) and Alector (ALEC)
Optimistic Buy Rating for Alector's AL002 Based on Promising Alzheimer's Disease Trial Biomarkers and TREM2 Signaling Efficacy
Alector: Cautious Hold Rating Ahead of Key Clinical Trial Milestones and Financial Assessment
Alector (ALEC) Receives a Buy From Barclays
TD Cowen Sticks to Their Buy Rating for Alector (ALEC)
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Alector (ALEC) and Cytokinetics (CYTK)
Alector's Promising Pipeline and Market Potential Affirm Buy Rating
Analysts Offer Insights on Healthcare Companies: Alector (ALEC), Viking Therapeutics (VKTX) and Zimmer Biomet Holdings (ZBH)
Alector (ALEC) Gets a Buy From BTIG
A Buy Rating for Alector: Innovating in Neurodegeneration With a Promising Immuno-Neurology Pipeline
Stifel Upgrades Alector to Buy, Stock Rallies 18%
Stifel Upgrades Alector to Buy, Raises Price Target to $15
Alector Analyst Ratings
Alector Analyst Ratings
Mizuho Maintains Buy on Alector, Lowers Price Target to $9
Alector Analyst Ratings
Mizuho Securities Trims Price Target on Alector to $9 From $10, Keeps Buy Rating
High Potential for Alector's AL002 in Alzheimer's Treatment: An In-depth Analysis of Shrader's Buy Rating Recommendation
No Data